Insulin and novel thioglycosides exert suppressive effect on human breast and colon carcinoma cells

Area of Science:

• Oncology
• Cancer Biology
• Drug Discovery

Background:

• Cancer therapies increasingly target specific cancer hallmarks.
• The Warburg effect, characterized by altered glucose metabolism, is a key feature of cancer cells.
• Dysfunctional glycometabolism presents a viable target for novel anticancer strategies.

Purpose of the Study:

• To design and evaluate novel thioglycoside compounds (A and B) as potential anticancer agents.
• To assess the synergistic effect of these compounds when combined with insulin in cancer cell lines.
• To elucidate the underlying mechanisms of action, including effects on apoptosis and glucose transport.

Main Methods:

• Cytotoxicity assays were performed on breast and colon cancer cell lines.
• Compounds were tested alone and in combination with insulin.
• Mechanistic studies included assessment of cell migration, motility, apoptosis, glucose transporter 1 (GLUT1) expression, and proapoptotic protein levels.

Main Results:

• Both thioglycoside A and B demonstrated significant cytotoxic effects against cancer cell lines.
• The antitumor activity of the compounds was markedly enhanced when cells were sensitized with insulin.
• Mechanistic investigations revealed modulation of apoptosis and glucose uptake pathways.

Conclusions:

• Thioglycoside compounds A and B exhibit promising antitumor properties.
• Combining these novel agents with insulin potentiates their anticancer effects, likely by exploiting the Warburg effect.
• Targeting cancer's increased glucose uptake and altered metabolism represents a promising therapeutic avenue.